Source: Halozyme Therapeutics and Antares Pharma This transaction is expected to close in the first half of 2022. Following the successful completion of the tender offer, Halozyme will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price. Halozyme intends to finance the transaction using existing cash on hand and new sources of debt. The transaction is not subject to a financing condition. Under the merger agreement, Halozyme will commence a cash tender offer to acquire all of the outstanding shares of Antares for $5.60 per share in cash. The Antares business consists of a royalty revenue-generating auto injector platform business and a commercial business with three proprietary commercial products. Halozyme Therapeutics, a San Diego, California-based biopharmaceutical company, has agreed to acquire Antares Pharma, an Ewing, New Jersey-based specialty pharmaceutical company, for approximately $960 million to create a drug-delivery and specialty product company. Halozyme To Acquire Antares Pharma for $960 M A roundup of mergers & acquisitions from Halyzome Therapeutics/Antares Pharma and Regeneron Pharmaceuticals/ Checkmate Pharmaceuticals.
0 kommentar(er)
